SCORED Trial (Sotagliflozin) Risk Index Calculator
- SCORED Trial (Sotagliflozin) Risk Index — explanation and clinical context
This calculator implements a trial-derived risk estimator based on SCORED trial aggregate results. SCORED enrolled adults with type 2 diabetes and chronic kidney disease and reported a primary composite event rate in the placebo arm of approximately 7.5 events per 100 patient-years (≈7.5% per year) and an estimated hazard ratio of 0.74 for the sotagliflozin arm versus placebo for the primary composite endpoint; the default values in this tool reflect these trial-level numbers. By default the tool uses the trial average baseline risk (7.5%/year) or you may supply your own estimated baseline annual risk (%) to reflect a different patient or population. The treated-event estimate is calculated assuming a constant proportional hazard (treated risk = baseline risk × HR).
Clinical interpretation: this tool provides an estimate of absolute and relative treatment effect for a one-year horizon using SCORED trial HRs. It is not a validated individualized prediction model; personalized risk depends on many patient-level factors not captured here. Use these estimates as transparent, trial-based approximations to inform discussions about expected absolute benefit and NNT when considering sotagliflozin in populations similar to SCORED participants.
Reference:
Bhatt DL, et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease (SCORED). NEJM and related SCORED publications; SCORED reported placebo event rate ≈7.5 per 100 patient-years and HR ≈0.74 for the primary composite. For trial details and secondary analyses see SCORED publications and FDA integrated review.
Discussion
No discussions yet. Be the first to comment.